Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE).

Lin ChangBrooks D CashAnthony J LemboDavid C KunkelBrett A EnglishBeatriz LindstromGuibao GuSharon SkareKye GilderStewart TurnerFabio CataldiDonald LipkisTack Jan

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2023)

gov: NCT04043455.

Keyphrases

irritable bowel syndrome
abdominal pain
double blind
placebo controlled
open label
clinical trial
randomized controlled trial
combination therapy